Left Ventricular Hypertrophy
📧 Sign up to get email alerts when something new happens for Left Ventricular Hypertrophy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension [Phase 4]
Phase 4 trial evaluating whether the combination of amlodipine and benazepril reduces left ventricular hypertrophy in patients with high-ris…
-
FDA approval · 2016-11-16FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s supplemental application for Losartan Potassium, marking an approval of changes to the generic pr…
-
CLINICAL_TRIALS trial_result · 2016-11-04Clinical Trial Update: Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study [Phase 4]
Phase 4 ALTERED study investigating whether allopurinol can regress left ventricular hypertrophy in patients with end-stage renal disease; t…
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? [Phase 4]
Phase 4 trial evaluating whether xanthine oxidase inhibitors can reduce left ventricular hypertrophy and improve endothelial function in pat…
-
CLINICAL_TRIALS trial_result · 2016-07-29Clinical Trial Update: Cardiac MR of Subclinical CVD: Impact of Age
This completed NHLBI trial evaluates cardiac MRI in subclinical cardiovascular disease. It investigates how age affects MRI findings.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-06-10FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for losartan potassium submitted by Alembic Pharmaceuticals Limited (ANDA 090428). This action u…
-
FDA approval · 2016-06-10FDA Approved: LOSARTAN POTASSIUM TABLETS, 25 MG — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approved Jubilant Cadista Pharmaceuticals Inc. to market Losartan potassium tablets, 25 mg, as a generic product under an ANDA supplemen…
-
FDA approval · 2016-06-09FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Losartan Potassium (generic) from Lupin Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2016-05-13Clinical Trial Update: Racial Differences in the Coronary Microcirculation
The NHLBI-sponsored trial evaluating racial differences in the coronary microcirculation has completed; the snippet does not provide specifi…
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: Hypertension in Hemodialysis Patients (Aim 3) [Phase 3]
A Phase 3 trial for hypertension in patients receiving hemodialysis was terminated, and its results were posted in January 2016.
-
CLINICAL_TRIALS trial_result · 2015-12-09Clinical Trial Update: Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients [NA]
A completed clinical trial evaluated vitamin D therapy for reducing cardiac damage in adults with hypertension and left ventricular hypertro…
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: Active Vitamin D Effect on Left Ventricular Hypertrophy [Phase 4]
Phase 4 trial evaluating active vitamin D for left ventricular hypertrophy in patients with chronic kidney disease and secondary hyperparath…
-
CLINICAL_TRIALS trial_result · 2015-10-27Clinical Trial Update: Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome [NA]
Clinical trial update reports on metabolic and cardiovascular effects of Armolipid Plus in subjects with metabolic syndrome.
-
CLINICAL_TRIALS trial_result · 2015-10-14Clinical Trial Update: Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease
This completed trial evaluated the effect of in-centre nocturnal hemodialysis on ventricular remodeling and cardiac function in patients wit…
-
FDA approval · 2015-08-12FDA Approved: LOSARTAN POTASSIUM — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original generic application for losartan potassium, a generic version of the hypertension medication l…
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study [Phase 4]
A Phase 4 pilot clinical trial evaluating the effects of everolimus in treating left ventricular hypertrophy after conversion from azathiopr…
-
CLINICAL_TRIALS research · 2015-06-19Clinical Trial Update: Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis [Phase 3]
A Phase 3 trial is evaluating the effects of high-dose atorvastatin in patients with surgical aortic stenosis. The document does not report …
-
CLINICAL_TRIALS trial_result · 2015-05-12Clinical Trial Update: Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan [NA]
Clinical trial update evaluating losartan to attenuate cardiac effects after arteriovenous fistula creation in patients with renal failure a…
-
CLINICAL_TRIALS research · 2015-05-12Clinical Trial Update: Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
This clinical trial update covers the CHART-2 study on chronic heart failure, with no current status reported.
-
FDA approval · 2015-03-31FDA Approved: LOSARTAN POTASSIUM TABLETS, 25 MG — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approved a supplemental application to add a 25 mg strength of Losartan Potassium Tablets, expanding the product's dosage options. The a…
-
FDA approval · 2015-02-13FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for Losartan Potassium from Solco Healthcare US, LLC.
-
FDA approval · 2014-12-11FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for Losartan Potassium from Solco Healthcare US, LLC.
-
FDA approval · 2014-09-25FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (AiPing Pharmaceutical, Inc.)
FDA approved a supplemental application for Losartan Potassium from AiPing Pharmaceutical, Inc. under an ANDA, indicating an additional appr…
-
CLINICAL_TRIALS trial_result · 2014-07-24Clinical Trial Update: ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling [Phase 4]
A Phase 4 trial comparing aliskiren and losartan evaluated biomarkers of myocardial remodeling in patients with hypertension and left ventri…
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients? [Phase 4]
Phase 4 clinical trial update assessing whether nebivolol can reverse inappropriate left ventricular mass in hypertensive patients; the stud…